CAT

863.78

-2.75%↓

286.16

+1.54%↑

GEV.US

1,014.05

-3.2%↓

RTX

176.01

+2.85%↑

220.74

+0.11%↑

CAT

863.78

-2.75%↓

286.16

+1.54%↑

GEV.US

1,014.05

-3.2%↓

RTX

176.01

+2.85%↑

220.74

+0.11%↑

CAT

863.78

-2.75%↓

286.16

+1.54%↑

GEV.US

1,014.05

-3.2%↓

RTX

176.01

+2.85%↑

220.74

+0.11%↑

CAT

863.78

-2.75%↓

286.16

+1.54%↑

GEV.US

1,014.05

-3.2%↓

RTX

176.01

+2.85%↑

220.74

+0.11%↑

CAT

863.78

-2.75%↓

286.16

+1.54%↑

GEV.US

1,014.05

-3.2%↓

RTX

176.01

+2.85%↑

220.74

+0.11%↑

Inicio・Lista de Acciones・Ocugen Inc

Ocugen Inc

Cerrado

1.34 -3.6

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.32

Máximo

1.38

Métricas clave
By Trading Economics
Ingresos	-1.5M -19M
Ventas	1.7M 1.5M
BPA	-0.06
Margen de beneficios	-1,250.946
Empleados	116
EBITDA	-987K -17M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+732.37% upside

Dividendos
By Dow Jones
Próximas Ganancias	31 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-125M 501M
Apertura anterior	4.94
Cierre anterior	1.34

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

0.6818 / 0.74 Soporte y Resistencia

Ocugen Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

18 may 2026, 23:10 UTC

Acciones populares

Stocks to Watch: Agilysys, XP

18 may 2026, 18:44 UTC

Principales Movimientos del Mercado

Claritev Shares Recover After Comments About DOJ

18 may 2026, 23:55 UTC

Ganancias

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 may 2026, 23:47 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

18 may 2026, 23:47 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 may 2026, 23:37 UTC

Charlas de Mercado

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 may 2026, 22:31 UTC

Adquisiciones, fusiones, absorciones

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 may 2026, 22:30 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 may 2026, 22:25 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 may 2026, 22:24 UTC

Adquisiciones, fusiones, absorciones

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 may 2026, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

18 may 2026, 20:50 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

18 may 2026, 20:25 UTC

Ganancias

Correct: XP 1Q Total Client Assets BRL1.53T

18 may 2026, 20:23 UTC

Ganancias

XP 1Q Total Client Assets BRL1.53B

18 may 2026, 20:19 UTC

Ganancias

XP 1Q Adj EPS BRL2.49 >XP

18 may 2026, 20:19 UTC

Ganancias

XP 1Q Rev BRL4.73B >XP

18 may 2026, 19:10 UTC

Charlas de Mercado

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 may 2026, 19:00 UTC

Ganancias

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 may 2026, 18:52 UTC

Charlas de Mercado

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 may 2026, 18:17 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 may 2026, 17:22 UTC

Charlas de Mercado

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 may 2026, 16:57 UTC

Adquisiciones, fusiones, absorciones

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 may 2026, 16:57 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

18 may 2026, 16:57 UTC

Charlas de Mercado

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 may 2026, 16:54 UTC

Adquisiciones, fusiones, absorciones

Vinci Doesn't Set Out Financial Details of Deal

18 may 2026, 16:50 UTC

Adquisiciones, fusiones, absorciones

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 may 2026, 16:49 UTC

Adquisiciones, fusiones, absorciones

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 may 2026, 16:49 UTC

Adquisiciones, fusiones, absorciones

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 may 2026, 16:48 UTC

Adquisiciones, fusiones, absorciones

Vinci Buys Canada's Modern Group of Companies

Comparación entre iguales

Cambio de precio

Ocugen Inc previsión

Precio Objetivo

By TipRanks

732.37% repunte

Estimación a 12 Meses

Media 11.57 USD 732.37%

Máximo 22 USD

Mínimo 7 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ocugen Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

Comprar

Mantener

Vender

De acuerdo con 7 analistas que ofrecen calificaciones bursátiles a para Ocugen Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

0.6818 / 0.74Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.